Highest-materiality recent filing
Zura Bio furnishes updated corporate presentation; no specific details disclosed in filing
Filing under Item 7.01 provides updated corporate presentation for investor meetings.
Shareholders approve amended equity plan at annual meeting, re-elect directors
Amended 2023 Equity Incentive Plan approved: 38.9M for, 17.4M against, 18.3M broker non-votes.
Zura Bio director Someit Sidhu resigns effective May 21; no disagreement cited
Someit Sidhu resigned from Zura Bio's board on May 20, effective May 21, 2026.
Zura Bio Q1 net loss $24.2M ($0.22/sh); advancing tibulizumab Phase 2 trials
Net loss of $24.2M ($0.22 per share) vs. $17.4M ($0.19) in Q1 2025.
CFO Eric Hyllengren departs; Marlyn Mathew named principal accounting/financial officer
CFO Eric Hyllengren separated from Zura Bio on April 20, 2026; separation not related to financial/operating results.
Zura Bio FY2025 net loss $99.4M; raised $144M in Feb 2026; tibulizumab data on track
Net loss attributable to Class A shareholders $99.4M ($1.06/share) vs $45.4M ($0.60) in 2024.
Zura Bio provides updated corporate presentation; no financial results disclosed
Updated corporate presentation furnished as Exhibit 99.1 for use at conferences and investor meetings.
Zura Bio presents Phase 2 TibuSURE trial design at SSc World Congress; no data yet
Design of Phase 2 TibuSURE trial evaluating tibulizumab (dual IL-17A/BAFF inhibition) in diffuse cutaneous systemic sclerosis accepted for poster presentation.
Zura Bio files 8-K/A to correct legal exhibits; no new business disclosure
Amendment only restates Exhibits 5.1 (legal opinion) and 23.1 (consent) from Feb 25, 2026 8-K.
Zura Bio prices $125M public offering of 18.2M shares at $6.25 and 1.8M pre-funded warrants
Offering: 18.2M Class A ordinary shares at $6.25/share, plus 1.8M pre-funded warrants at $6.249 each.
Zura Bio appoints Eisner and Nirula to board; Graham resigns
Neil Graham resigned from Zura's board effective Feb 21, 2026; departure not due to any disagreement.
Zura Bio issues updated corporate presentation; no specific new facts in filing text
Presentation posted as Exhibit 99.1, dated February 11, 2026, for use at conferences and investor meetings.
Zura Bio announces CEO resignation and appointment of Sandeep Kulkarni as new CEO
Robert Lisicki resigned as CEO and director effective January 21, 2026, after medical leave since October 2025.
Zura Bio expands HS trial to 225 patients; expects Q4 2026 data; cash through 2027
Phase 2 TibuSHIELD trial in HS expanded from 180 to 225 participants; topline data expected Q4 2026.
Zura Bio terminates prior Stone Peach/BAFFX17 agreements, issues 8.66M shares to Athanor Capital
Terminated Letter Agreements with Stone Peach and BAFFX17; entered new Athanor Agreement on Dec 29, 2025.
Director Arnout Ploos van Amstel resigns from Zura Bio Board effective Dec 11, 2025
Arnout Ploos van Amstel resigned from the Board and Nominating and Governance Committee.
Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027
Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.
CEO Robert Lisicki takes medical leave; COO Kim Davis appointed interim CEO effective Oct 10
CEO Robert Lisicki informed Zura Bio of a medical leave of absence starting October 10, 2025.
Zura Bio adopts Executive Severance Benefit Plan for CEO and named executives
CEO: 12 months base salary on regular termination; 18 months + 150% target bonus on change-in-control termination.
Zura Bio files updated corporate presentation for investor meetings
Updated corporate presentation dated September 4, 2025, filed as Exhibit 99.1.
Zura Bio to present at Cantor Fitzgerald Global Healthcare Conference Sept 4
Fireside chat at 2:45 PM ET on Sept 4, 2025 in New York.
Zura Bio Q2 2025 net loss $16.0M; cash $154.5M funds through 2027
Cash and cash equivalents of $154.5M as of June 30, 2025, expected to fund operations through 2027.
Zura Bio appoints Eric Hyllengren as CFO; Verender Badial steps down effective July 7, 2025
Eric Hyllengren appointed CFO effective July 7, 2025; previously COO/CFO at Atara Biotherapeutics and 15 years at Amgen.
Zura Bio posts updated corporate presentation for Jefferies conference
Updated corporate presentation filed as Exhibit 99.1 on June 4, 2025.
Zura Bio to present corporate overview at Jefferies Global Healthcare Conference June 4, 2025
Senior leadership team will present at Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 PM ET in New York.
Zura Bio shareholders elect all nine director nominees and ratify auditor at 2025 AGM
All nine director nominees elected; Dan Becker received 32,757,554 for, 36,056 against.
Zura Bio launches global Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa
TibuSHIELD will enroll ~180 adults with moderate-to-severe HS across US, Canada, and Europe.
Zura Bio Q1 net loss $17.4M; cash $170.6M; trial on track
Net loss $17.4M ($0.19/sh) vs $7.7M ($0.02/sh) in Q1 2024; R&D spend $10.5M (+192% YoY).
Zura Bio exchanges 6.5M shares for pre-funded warrants at $0.001/share
Venrock surrenders 3.5M shares; AI Biotechnology surrenders 3.0M shares for no consideration.
Zura Bio FY 2024 net loss $45.4M ($0.60/sh); cash $176.5M, runway to 2027
Cash and cash equivalents $176.5M as of Dec 31, 2024, up from $99.8M at year-end 2023; sufficient to fund operations through 2027.
Zura Bio furnishes updated corporate presentation; no material new details disclosed.
Company provided updated corporate presentation for investor meetings on March 25, 2025.
Zura Bio to present at Leerink Partners Global Healthcare Conference on March 11, 2025
Members of senior leadership will participate in a fireside chat on Tuesday, March 11, 2025 at 1:40 p.m. ET.
Zura Bio files updated corporate presentation; no specific details included in filing
Updated corporate presentation furnished as Exhibit 99.1 on January 13, 2025.
Zura Bio launches Phase 2 TibuSURE study of tibulizumab in systemic sclerosis
TibuSURE is a global Phase 2 double-blind, placebo-controlled trial in ~80 adults with early diffuse cutaneous systemic sclerosis.
Zura Bio to present at Piper Sandler 36th Annual Healthcare Conference on Dec 3, 2024
Senior leadership to hold fireside chat at 9:00 AM ET on December 3, 2024.
Zura Bio submits Phase 2 protocol for tibulizumab in systemic sclerosis to FDA
Protocol submitted to open IND for Phase 2 study of tibulizumab (IL-17A/BAFF dual antagonist) in adults with systemic sclerosis.
Zura Bio Q3 net loss $22.9M; cash $188.2M; Phase 2 trials on track for SSc and HS
Net loss of $22.9M ($0.26 per share) vs $8.3M ($0.18) in Q3 2023; G&A up $7.1M on one-time stock comp and warrant exchange.
Zura Bio to participate in two November investor conferences (fireside chat, meetings)
Fireside chat at Guggenheim Inaugural Healthcare Innovation Conference on Nov 12, 2024 at 1:00 PM ET.
Zura Bio shareholders elect all nine directors and ratify auditor at 2024 AGM
All nine director nominees elected: Neil Graham, Jennifer Jarrett, Sandeep Kulkarni, Robert Lisicki, Amit Munshi, Arnout Ploos van Amstel, Steve Schoch, Someit Sidhu, Parvinder Thiara.
Zura Bio CSO Michael Howell departs effective Oct 15, 2024; no successor named
Chief Scientific Officer Michael Howell separated from Zura Bio on October 15, 2024.
Zura Bio files updated corporate presentation; no material financial details in filing text
Corporate presentation dated September 9, 2024 furnished under Item 7.01 for investor meetings.
Zura Bio to present at three investor conferences in September 2024
Presenting at H.C. Wainwright 26th Global Investment Conference on Sept 11, 2024 at 11:30 a.m. ET.
Venrock affiliates surrendered 4,000,000 Class A ordinary shares for no consideration; shares cancelled.
Zura Bio provides updated corporate presentation; no material financial updates in filing
Presentation intended for use at upcoming conferences and investor meetings.
Zura Bio reports Q2 2024 net loss of $12.7M, cash of $188.4M; plans Phase 2 starts for tibulizumab
Net loss of $12.7M ($0.17/share) vs $44.9M ($1.31/share) in Q2 2023; reduction driven by prior-year acquisition costs.
97.2% of public warrants (6,703,428) and 69% of private warrants (4,080,580) tendered, exchanged for 3,235,184 Class A ordinary shares.
Zura Bio reports 97.2% of public warrants and 69% of private warrants tendered in exchange offer
6,703,428 public warrants (~97.2%) and 4,080,580 private placement warrants (~69.0%) validly tendered; settlement expected by Aug 12, 2024.
Zura Bio settles with former CEO Someit Sidhu; pays $556,692 plus stock vesting
Settlement includes $139,173 pay in lieu of notice, $139,173 compensation, and $278,346 severance.
Zura Bio launches warrant exchange offer for 0.30 shares per warrant; expires Aug 8, 2024
Exchange offer for IPO warrants: 0.30 Class A ordinary shares per warrant, up to 3,842,999 shares total.
Zura Bio boosts CEO Lisicki's salary to $585k, bonus target to 50%
CEO Robert Lisicki's base salary increased from $440k to $585k, retroactive to April 8, 2024.
On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of directors of the Company effective as of May 21, 2026.
On and effective October 15, 2024, Michael Howell, the Chief Scientific Officer of Zura Bio Limited (the “ Company ”), was separated from the Company.
On March 24, 2024, the board of directors of ZURA (the “ Board ”) approved a Chief Executive Officer (“ CEO ”) transition from Someit Sidhu, our Founder, CEO and Director, to Robert Lisicki, effective April 8, 2024.
Mr. Lisicki will join the Board as a non-independent Director increasing its membership from nine Directors to ten.
Mr. Lisicki, the Company’s current President and Chief Operating Officer, will be promoted to the Company’s Chief Executive Officer on April 8, 2024.
On January 3, 2024, the Company appointed Mr. Robert Lisicki as President and Chief Operating Officer, effective as of January 8, 2024 (the “Commencement Date”).
On January 4, 2024, Dr. Chris Cabell and Zura Bio Limited (the “Company”) agreed that he will be stepping down as the Company’s Chief Medical Officer and Executive Vice President, effective on January 15, 2024.
On November 30, 2023, Zura Bio Limited (the “Company”) appointed Dr. Kiran Nistala as Executive Vice President, effective as of November 27, 2023
On June 22, 2023, the Board appointed Parvinder Thiara to fill the vacancy on and serve as a member of the Board, to serve until the next annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier death, resignation or removal.
Chris Cabell, the Company’s Chief Medical Officer and Executive Vice President, will be taking on Dr. Klassen’s duties going forward.
On April 6, 2023, Preston Klassen notified Zura Bio Limited (the “Company”) that he intended to resign as the Company’s President and Chief Operating Officer.
Someit Sidhu, our Chief Executive Officer, was elected as a director and Amit Munshi, Sandeep Kulkarni, Garry Neil, Steve Schoch, Jennifer Jarrett and Neil Graham were elected as non-employee directors.
Max materiality 0.90 · Median 0.50 · Most common event other_material